We hope you’re doing well 😄.
We would like to share with you that last week we began the analytical validation of the final version of the CytoCatch™ isolation platform, one of the two devices that constitute our technology and makes it possible to isolate CTCs from other blood components.
This validation is fundamental for any medical or scientific device built to measure an analyte (the constituent of the sample to be analyzed, in our case the CTCs). The tests carried out during this validation are designed to ensure that our platform’s performance is optimal and the results obtained are reproducible. Here, our device will be extensively tested to assess key parameters, such as capture efficiency, purity, sensitivity, working range, precision, and accuracy. This has to be made before the device’s clinical validation, where a clinical study is going to be conducted in order to collect clinical data.
Even though this is just the beginning, and this validation will last for several months, we are thrilled because the first tests carried out yielded very positive results. Our device consistently had over 94% capture efficiency when processing blood samples of 7.5 mL spiked with 100 cancer cells. This means that our device was able to capture over 94 of these cells in every run performed, which is in line or even higher than our competitors’ yield 😎.
We are deeply thankful to all the people who already reserved their investment 🤗. At the moment, we are still in the Test The Waters (TTW) stage, in which you can reserve your investment without committing until the campaign goes officially live. If you reserve during the TTW stage you will receive 10% bonus shares when you confirm the investment.
Once again, thank you for all your support!
Delee Team 💙